Title : The clinical development of FLT3 inhibitors in acute myeloid leukemia.

Pub. Date : 2011 Oct

PMID : 21895538






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Newer, more potent FLT3 inhibitors such as sorafenib and AC220 possess the ability to achieve more sustained in vivo inhibition of FLT3 and have shown highly promising activity in early clinical studies. quizartinib fms related receptor tyrosine kinase 3 Homo sapiens
2 Newer, more potent FLT3 inhibitors such as sorafenib and AC220 possess the ability to achieve more sustained in vivo inhibition of FLT3 and have shown highly promising activity in early clinical studies. quizartinib fms related receptor tyrosine kinase 3 Homo sapiens